Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Milan – page 61

2 391 clinical trials in Milan, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Milan at a glance
2 391
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 391 trials in Milan

Open in trial search

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Breast neoplasm

Recruiting

Study on the Effects of Selumetinib, Bicalutamide, and Olaparib in Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bicalutamide
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Cholangiocarcinoma

Recruiting

Study of Radioembolization Combined with Cisplatin, Gemcitabine and Durvalumab Treatment in Patients with Unresectable Liver Cholangiocarcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Ospedale San Raffaele S.r.l.

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Recruiting
Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Adenocarcinoma gastric

Recruiting

Study on Pressurized Intraperitoneal Aerosol Chemotherapy with Fluorouracil for Patients with Gastric Cancer with Peritoneal Metastases

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Systemic lupus erythematosus

Recruiting

Study on Steroid Withdrawal in Systemic Lupus Erythematosus Patients Using Prednisone

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Azienda Ospedaliero Universitaria Pisana

Dry age-related macular degeneration

Recruiting

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Janssen Cilag International

Breast cancer+1

Recruiting

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Acute myeloid leukaemia+3

Recruiting

Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ponatinib
  • Sponsor:Incyte Biosciences International S.a.r.l.

Atrial fibrillation+2

Recruiting

Study on Apixaban and Edoxaban for Preventing Stroke in Patients with Recent Perioperative Atrial Fibrillation After Noncardiac Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Hamilton Health Sciences Corporation

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Milan

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer prevention, and advanced solid tumors. Studies include evaluation of novel therapeutic approaches and diagnostic methods.

  • Metastatic Colorectal Cancer Treatment
  • Breast Cancer Prevention Strategies
  • Advanced Solid Malignancies

Research emphasizes personalized treatment approaches and preventive interventions for high-risk patients.

02 Neurological Disorders

Research initiatives targeting neurodegenerative conditions and chronic headache disorders, with studies examining innovative therapeutic approaches.

  • Frontotemporal Dementia
  • Parkinson's Disease
  • Migraine Treatment

Focus on developing targeted therapies and understanding disease mechanisms.

03 Immunology and Infectious Diseases

Studies investigating treatments for autoimmune conditions and infectious diseases, including preventive approaches and therapeutic interventions.

  • Immune Thrombocytopenia
  • RSV Prevention
  • HIV Prevention

Emphasis on developing novel preventive strategies and therapeutic solutions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.